PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab).

Please see full Prescribing Information available at www.bms.com.

The company will provide additional details on the approval in a press release to follow.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global pharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com, or follow us on Twitter at http://twitter.com/bmsnews.

    CONTACT: Bristol-Myers Squibb Company
             Media:
             Sarah Koenig, 609-252-4145
             sarah.koenig@bms.com
             or
             Carrie Fernandez, 609-419-5448
             carrie.fernandez@bms.com
             or
             Christina Trank, 609-419-5497
             christina.trank@bms.com
             or
             Investors:
             John Elicker, 609-252-4611
             john.elicker@bms.com
             or
             Ranya Dajani, 609-252-5330
             ranya.dajani@bms.com

    Source: Bristol-Myers Squibb Company